Improving the appearance of atrophic facial scars in patients Skin and Connective Tissue Diseases
Conditions
Interventions
This study is a randomized controlled trial, including 2 groups of patients with atrophic facial scars - the control group will receive nanofat grafting. In contrast, the experimental group will rece
Sponsors
Damascus University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with atrophic linear facial scars 2. The length of the scar is more than 2 centimeters 3. Patients older than 18 years old 4. No systemic disease and syndromes 5. Previously untreated scars
Exclusion criteria
Exclusion criteria: 1. Patients with acute skin disease 2. Patients with bleeding disorder 3. Patients has gone through severe weight gain/loss during the past few months 4. Skinny patients (does not have enough fat tissue in the donor sites)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scar quality from the perspectives of the patient and the clinician measured using the Patient And Observer Scar Assessment Scale (POSAS) at baseline (T0: preoperative), 3 (T1) and 6 (T2) months postoperative | — |
Secondary
| Measure | Time frame |
|---|---|
| The following secondary outcome measures will be assessed at baseline (T0: preoperative), 3 (T1) and 6 (T2) months postoperative: 1. Scar appearance measured in 4 grades (Level 1: Macular Scar; Level 2: Mild Scar; Level 3: Moderate Scar; and, Level 4: Severe Scar) by 3 observers using the Goodman and Baron Scale 2. Aesthetic improvement measured using the Global Aesthetic Improvement Scale (7 levels: -3 = Very Much Worse; -2 = Much Worse; -1 = Worse; 0 = No Change; 1 = Improved; 2 = Much Improved; and, 3 = Very Much Improved) | — |
Countries
Syria
Contacts
Public ContactMhd Anas ;Mhd Anas Alnemr;Alnemr
;
Outcome results
None listed